This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fallik, D. Articles by Praz, F. Search for Related Content PubMed PubMed Citation Articles by Fallik, D. Articles by Praz, F.

Microsatellite Instability Is a Predictive Factor of the Tumor Response to Irinotecan in Patients with Advanced Colorectal Cancer¹

Departments of Medicine [D. F., V. B., M. D.] and Pathology [F. B., C. M., J-C. S.], Institut Gustave Roussy, Centre National de la Recherche Scientifique Unité Mixte de Recherche 1598 [D. F., F. P.], and Unité Propre de Recherche 2169 [J. V., S. J., F. P.], Villejuif, France

The aim of our study was to assess the relationship between colorectal tumor responsiveness to irinotecan and microsatellite instability (MSI), a feature of colorectal tumors with DNA mismatch repair defect. Seventy-two patients with metastatic colorectal cancer were included in our retrospective study. A complete response to irinotecan was observed in 1 patient and a partial response in 10 patients, whereas 61 patients did not respond to this treatment. We analyzed the protein expression of hMLH1, hMSH2, and BAX by immunohistochemistry, determined the MSI phenotype, and looked for mutations in the coding repeats located in the transforming growth factor ß-RII, BAX, hMSH3, and hMSH6 genes. All 44 tumors analyzed expressed detectable levels of hMLH1; 1 tumor lacked hMSH2 staining, whereas 4 tumors showed a marked decrease in BAX expression. A better response to irinotecan was observed in the patients whose tumors have lost BAX expression (P < 0.001). Among the 7 tumors that displayed a MSI-H phenotype, 4 responded to irinotecan, whereas only 7 of the 65 MSI-L/ microsatellite stable tumors did (P = 0.009). Seven of the 72 tumors had inactivating mutations in the coding repeats of the target genes. Three tumors displayed a mutation in the poly-A10 tract of the transforming growth factor ß-RII gene, associated with a 1-bp deletion in the poly-A8 tract of hMSH3 in one tumor and with a 1-bp deletion in the poly-G8 tract of BAX in another. Four tumors displayed mutations in the poly-G8 repeat of BAX, whereas 2 mutations in hMSH6 and hMSH3 were characterized. Among the 7 tumors with mutations in these target genes, 5 responded to irinotecan, whereas only 6 of the other 65 tumors did (P < 0.001), indicating that MSI-driven inactivation of target genes modifies tumor chemosensitivity. Our observations allowed us to define the first useful predictive criteria for irinotecan response in patients with colorectal cancer.

This article has been cited by other articles:

				M. Viana-Pereira, I. Almeida, S. Sousa, B. Mahler-Araujo, R. Seruca, J. Pimentel, and R. M. Reis Analysis of microsatellite instability in medulloblastoma Neuro Oncology, October 1, 2009; 11(5): 458 - 467. [Abstract] [Full Text] [PDF]

				J. C. KIM, S. A. ROH, D. H. CHO, T. W. KIM, S. N. YOON, C. W. KIM, C. S. YU, S. Y. KIM, and Y. S. KIM Chemoresponsiveness Associated with Canonical Molecular Changes in Colorectal Adenocarcinomas Anticancer Res, August 1, 2009; 29(8): 3115 - 3123. [Abstract] [Full Text] [PDF]

				G. DES GUETZ, B. UZZAN, P. NICOLAS, O. SCHISCHMANOFF, G.-Y. PERRET, and J.-F. MORERE Microsatellite Instability does not Predict the Efficacy of Chemotherapy in Metastatic Colorectal Cancer. A Systematic Review and Meta-analysis Anticancer Res, May 1, 2009; 29(5): 1615 - 1620. [Abstract] [Full Text] [PDF]

				E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al. Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Clin. Cancer Res., April 15, 2009; 15(8): 2829 - 2839. [Abstract] [Full Text] [PDF]

				M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton, H. P. Hahn, M. Hall, B. Damas, S. D. Jewell, R. J. Mayer, R. M. Goldberg, L. B. Saltz, et al. Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 J. Clin. Oncol., April 10, 2009; 27(11): 1814 - 1821. [Abstract] [Full Text] [PDF]

				R. Rodriguez, L. T. Hansen, G. Phear, J. Scorah, M. Spang-Thomsen, A. Cox, T. Helleday, and M. Meuth Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11 Clin. Cancer Res., September 1, 2008; 14(17): 5476 - 5483. [Abstract] [Full Text] [PDF]

				Y. Kazama, T. Watanabe, T. Kanazawa, J. Tanaka, T. Tanaka, and H. Nagawa Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features J. Clin. Pathol., June 1, 2007; 60(6): 701 - 704. [Abstract] [Full Text] [PDF]

				H F A Vasen, G Moslein, A Alonso, I Bernstein, L Bertario, I Blanco, J Burn, G Capella, C Engel, I Frayling, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) J. Med. Genet., June 1, 2007; 44(6): 353 - 362. [Abstract] [Full Text] [PDF]

				J M Carethers Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut, June 1, 2006; 55(6): 759 - 761. [Full Text] [PDF]

				P. Benatti, R. Gafa, D. Barana, M. Marino, A. Scarselli, M. Pedroni, I. Maestri, L. Guerzoni, L. Roncucci, M. Menigatti, et al. Microsatellite Instability and Colorectal Cancer Prognosis Clin. Cancer Res., December 1, 2005; 11(23): 8332 - 8340. [Abstract] [Full Text] [PDF]

				J. Viguier, V. Boige, C. Miquel, M. Pocard, B. Giraudeau, J.-C. Sabourin, M. Ducreux, A. Sarasin, and F. Praz ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6212 - 6217. [Abstract] [Full Text] [PDF]

				S. Jacob, C. Miquel, A. Sarasin, and F.ço. Praz Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines Nucleic Acids Res., January 7, 2005; 33(1): 106 - 113. [Abstract] [Full Text] [PDF]

				E Domingo, P Laiho, M Ollikainen, M Pinto, L Wang, A J French, J Westra, T Frebourg, E Espin, M Armengol, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing J. Med. Genet., September 1, 2004; 41(9): 664 - 668. [Abstract] [Full Text] [PDF]